Abstract
Background
The prognosis of scirrhous gastric cancer remains poor despite extended surgery or adjuvant or neoadjuvant chemotherapy. A pilot study of S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan), an oral 5-fluorouracil derivative, for neoadjuvant chemotherapy unexpectedly showed good response and a promising effect on survival. Therefore, the Japan Clinical Oncology Group conducted a phase II trial to confirm the efficacy of S-1 for neoadjuvant chemotherapy against resectable scirrhous gastric cancer.
Methods
Patients were eligible if they had typical scirrhous gastric cancer invading more than half of the stomach, and resectable disease confirmed by laparoscopic staging. The treatment schedule consisted of two courses (each, 4-week administration and 2-week withdrawal) of S-1 (100–120 mg/body per day), followed by radical surgery.
Results
Fifty-five eligible patients were registered. Three completed only one course of the neoadjuvant chemotherapy, whereas 52 completed two courses. Toxicity was acceptable, with a few grade 3 (5.5%) events, but no grade 4 adverse events. The response rate was 32.6% in 43 evaluable patients. Of the 55 patients, 2 refused operation, 1 developed lung metastasis, and 52 underwent laparotomy. The curative resection rate was 80.8%, with acceptable morbidity and no mortality. The survival curve at 2 years’ follow up showed a better survival rate than that of the historical controls, but did not reach the expected survival rate.
Conclusion
S-1 neoadjuvant chemotherapy appeared feasible and showed positive effects against scirrhous gastric cancer; however, the survival rate with S-1 did not reach the expected rate required when selecting an agent for a phase III trial to confirm the effectiveness of neoadjuvant chemotherapy against scirrhous gastric cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Mai M, Ogino T, Ueda H, Ooi A, Takahashi Y, Sawaguchi K, et al. Study on neoadjuvant chemotherapy of Borrmann 4 type carcinoma of the stomach and its clinical significance. Nippon Gan Chiryo Gakkai Shi (J Jpn Soc Cancer Ther) 1990;25:586–597.
Maeda O, Iwase H, Mamiya N, Nakamura M, Mizuno T, Nishio Y, et al. A case of scirrhous cancer of the stomach which survived for more than 5 years after neoadjuvant chemotherapy with UFT (uracil and tegafur) and cisplatin. Intern Med 2000;9:239–244.
Eriguchi M, Osada I, Fujii Y, Takeda Y, Yoshizaki I, Akiyama N, et al. Pilot study for preoperative administration of 1-OHP to patients with advanced scirrhous type gastric cancer. Biomed Pharmacother 1997;51:217–222.
Suga S, Iwase H, Shimada M, Nishio Y, Ichihara T, Ichihara S, et al. Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil, tegafur and cisplatin. Intern Med 1996;35:930–936.
Takahashi S, Kinoshita T, Konishi M, Nakagohri T, Inoue K, Ono M, et al. Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer. Gastric Cancer 2001;4;192–197.
Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Miyachi Y et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivation for advanced and recurrent gastrointestinal cancers. Oncology 1999;57:202–210.
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-04 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715–1720.
Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191–197.
Kinoshita T, Konishi M, Nakagohri T, Inoue K, Oda T, Takahashi S, et al. Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer. A pilot study. Gastric Cancer 2003;6:40–44.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—second English edition—. Gastric Cancer 1998;1:10–24.
Author information
Authors and Affiliations
Additional information
(on behalf of the Gastric Cancer Surgery Study Group of the Japan Clinical Oncology Group)
Rights and permissions
About this article
Cite this article
Kinoshita, T., Sasako, M., Sano, T. et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer 12, 37–42 (2009). https://doi.org/10.1007/s10120-008-0496-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10120-008-0496-1